Drug and device-makers may be able to get their antimicrobial drugs and antimicrobial susceptibility tests (AST) to the US market simultaneously if they coordinate their regulatory submissions, according to a new FDA draft guidance.
The proposed guidance from the agency's drug and device centers recommends developers of antimicrobial drugs and ASTs coordinate...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?